Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like she's got legs. Been busy on the ARNA board all day. Looks like she could hit $12 real quick. Hopefully tis one breaks $3 in the next couple of weeks.
I was thinking that the $2.68 was pretty solid. Can't tell if the selling is real or just the mm's but I feel the current level is somewhat close to bottom if not bottom. I picked up 35K shares today at $2.375 average so we'll see how close I am. The stock is 82% inside owned so it will be ineresting to see if there is any selling going on. Also intereting, is the fact that Astellas paid the $125M to partner on TIVO and their market cap is currntly at $121M
I would say to do your own DD but I bought today because I think it's oversold. They have a pretty good pipeline and there could be some suprises, ie; firing of management, Astellas offer, Good phase II results. They have a ton of cash on hand so don't expect any offerings too soon as I'm sure they want the pps to rise back up before any offerings. I'm just going to sit for now.
Seems to be some pretty good buying today.
With approximately $3.50 cash per share, this seems like a very good entry point. A little good news could send this north quickly.
I think you may be right. I took a bath on this last week and sold at $2.82. Just got back in for 20K shares at $2.39. I think it's way oversold now so maybe I can make some of my loss back.
Me too, I had 10K shares at $5.27 and just tripled down for an average of $3.57. Would love to see it come back soon to at least that level. I think anything under $3 is underbaked in my opinion.
Exactly my thoughts. It would be nce to see a BMY offer thrown out there for about $2
It will more than likely rise slowly to .60 over the next 8-10 trading sessions as accumulation takes place. I did a little more accumulating myself this morning again. Anything can happen here, but I have very good feelings on TZYM. We shall see.
I think we will start rising from here. I think that those who wanted to sell sold on Wednesday and Thursday and Friday was an indication to me that the sellers are gone. L2 is lined up pretty good. I also think that the insiders may start trading this up now that the merger news is three days old.
Looks like some happenings while I was on vacation last week! I haven't really been able to wrp my arms around this yet as it is very complicated. Any opinions out there as to whether this has some legs or not?
Looks like a lot of others are watching it right now too. Let's get this thing over .63 which is cash alone before any announcements.
Looks like you are there already!
Looking like the come back kid to me. Getting ready to blst off again. See you at .60 by EOD
Seeking Alpha article just published.
http://seekingalpha.com/article/1361701-are-we-watching-celsion-rise-from-the-grave?source=yahoo
It was for me this morning!
Always wanting to shake the trees.
Be nice to see them snatch it up for $3!
I'll take that!
Absolutely, especially since I'm sitting on enough shares to buy a small island.
Multi-day runner/buyout news imo.
1,784,000 buys/998,000 sells today so far.
Nice to see this come alive here. Maybe something will be announced soon. I've always had a good gut feeling about this one and hopefully it will be my first bagger.
Indeed it is. Wondering what all the commotion is about. Hopefully something is cooking!
This is crazy today! What is all the spike up and volume about?
Yea, something is up today, be intersting to find out what's going on.
Maybe some institutional buying?
What is the reason for the spike? No news out besides the Zack's upgrade. Is there some news coming maybe?
All lined up at .44 on L2. Zachs upgrade must have been of some help for us here. Just waiting and watching now.
Very nice! Thanks for sharing.
Been loading again this week between .425 to .435. Ready for blast off now!
I am very happy for you, my turn now!
Looks like you have a runner here jimmyjam. A little more exciting than watching the paint dry on the other board.
You are absolutely correct. Why is it then, that the transaction doesn't show up on MFFAIS as a sold transaction. Was some other type of transaction performed, like a trade or such? Odd.
15.3M cash at end of 4Q, add in 1.6M BMS payment and deduct 1.2 admin expense at the most for 1Q and we are sitting at 15.7M in the bank. That equates to .5688 pps at cash only. We are sitting at a 28% discount to cash at yesterday's close of .42. This doesn't take into consideration any value of MATCH at all. BMS must think it's worth some bucks otherwise they wouldn't be committing to future 80M milestone possibilities. No insiders have been selling and management has lots of connections to find a buyer. Hired Stiefel and Skadden to broker a deal, just a matter of time before an announcement comes out as it's been 10 weeks since the announcement. Just waiting now. Not much downside here IMO.
Read this interesting tid bit from my DD today.
Alex Zisson is a diector on the TZYM board. He is also a partner in the firm Thomas McNerney & Partners who just so happens to be the largest inside holder at 3M shares. Here's what I read:
From the Tranzyme website:
Alex Zisson has served as one of our directors since May 2005. Since 2002, Mr. Zisson has been a Partner at Thomas, McNerney & Partners, a prominent health care venture capital firm that invests in life science and medical technology companies at all stages of development. He is currently a board member of several private life sciences companies, including Clarus Therapeutics, Inc, and Celator Pharmaceuticals, Inc. Before joining Thomas, McNerney & Partners, he spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan H&Q). During his tenure at H&Q, Mr. Zisson led research teams covering the biotechnology, specialty pharmaceuticals, large-cap pharmaceuticals, drug delivery and diagnostics industries. After the merger of Chase H&Q and JPMorgan, Mr. Zisson also became the firm's Health Care Strategist. He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa. Mr. Zisson serves on the board of directors of numerous life sciences companies, has extensive knowledge of the health care and biopharmaceutical industries and has been instrumental in our development since joining our board in 2005.
From the Thomas McNerney wesite:
Alex joined Thomas, McNerney & Partners in 2002 and is currently a board member of Celator Pharmaceuticals, Inc., Clarus Therapeutics, Inc., InnoPharma, Inc., and Tranzyme Pharma, Inc. (TZYM). Before joining the firm, he spent 11 years in the research department at Hambrecht & Quist (and its successor firms Chase H&Q and JPMorgan H&Q). During his tenure at H&Q, Alex led research teams covering the biotechnology, specialty pharmaceutical, large-cap pharmaceutical, drug delivery and diagnostic industries. He was the lead analyst on 10 book-running IPOs and 20 book-run secondary offerings, raising over $2 billion for health care companies. In 1997, Alex was named a Managing Director and began assuming management responsibilities for the health care research group and the firm's annual January conference. After the merger of Chase H&Q and JPMorgan, he became the firm's Health Care Strategist. Alex was named twice in The Wall Street Journal's All-Star Analysts Survey, including during his last year at JPMorgan, when he placed in all three categories: stock picking (#1 in pharmaceuticals), earnings estimate accuracy (tied for #2), and 'home run' hitting (#8 across all industries). He graduated magna cum laude from Brown University, where he was elected to Phi Beta Kappa.
I found this to be interesting, hope it's not boring for the board
I think it will pay off. I just added to my position today also. This thing is poised for a reversal and I can't believe we are buying at these prices. It's priced way under cash and the company should have no net burn this and next quarter imo since they stopped all R & D and cranked down their expenses. MATCH and the BMS partnership have to have some value also. I'm not a patient trader and normally don't stick around this long but I think it will be worth the wait.
Hopefully I hear from you when we sell at $3
Amen to that. Added 10% to my position again today.
Should we all sell right now?